

## **Mpox (monkeypox) knowledge, concern, willingness to change behaviour, and seek vaccination: Results of a national cross-sectional survey**

James MacGibbon<sup>1</sup>, Vincent Cornelisse<sup>2,3</sup>, Anthony K J Smith<sup>1</sup>, Timothy R Broady<sup>1</sup>,  
Mohamed A Hammoud<sup>2</sup>, Benjamin R Bavinton<sup>2</sup>, Heath Paynter<sup>4</sup>, Matthew Vaughan<sup>5</sup>,  
Edwina J Wright<sup>6,7,8</sup>, and Martin Holt<sup>1</sup>

<sup>1</sup> Centre for Social Research in Health, UNSW Sydney, Sydney, NSW, Australia

<sup>2</sup> Kirby Institute, UNSW Sydney, Sydney, NSW, Australia

<sup>3</sup> NSW Health, Sydney, NSW, Australia

<sup>4</sup> The Australian Federation of AIDS Organisations, Sydney, NSW, Australia

<sup>5</sup> ACON, Sydney, NSW, Australia

<sup>6</sup> Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia

<sup>7</sup> Burnet Institute, Melbourne, Victoria, Australia

<sup>8</sup> The Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia

Corresponding author:

James MacGibbon

[j.macgibbon@unsw.edu.au](mailto:j.macgibbon@unsw.edu.au)

## ABSTRACT

**Background:** We assessed knowledge and concern about mpox, acceptability of behavioural changes to reduce transmission risk, and willingness to be vaccinated among gay, bisexual and queer-identifying men and non-binary people.

**Methods:** We conducted a national, online cross-sectional survey with a convenience sample between August and September 2022. Participants were recruited through community organisation promotions, online advertising, and direct email invitations. Eligible participants were gay, bisexual or queer; identified as male (cisgender or transgender) or non-binary; aged 16 years or older; and lived in Australia. The main outcome measures were: knowledge and concern about mpox; recognition of mpox symptoms and transmission routes; vaccination history; acceptability of behavioural changes to reduce mpox risk, and willingness to be vaccinated.

**Results:** Of 2287 participants, most participants were male (2189/2287; 95.71%) and gay (1894/2287; 82.82%). Nearly all had heard about mpox (2255/2287; 98.60%), and the majority were concerned about acquiring it (1461/2287; 64.42%). Most of the 2268 participants not previously diagnosed with mpox identified skin lesions (2087; 92.02%), rash (1977; 87.17%), and fever (1647; 72.62%) as potential symptoms, and prolonged and brief skin-to-skin contact as potential ways to acquire mpox (2124, 93.65%; and 1860, 82.01% respectively). The most acceptable behavioural changes were reducing or avoiding attendance at sex parties (1494; 65.87%) and sex-on-premises venues (1503; 66.40%), and having fewer sexual partners (1466; 64.64%). Most unvaccinated and undiagnosed participants were willing to be vaccinated (1457/1733; 84.07%).

**Conclusions:** People at risk of mpox should be supported to adopt acceptable risk reduction strategies during outbreaks and seek vaccination.

Keywords: men who have sex with men, gay and bisexual men, vaccination, attitudes,  
Australia, monkeypox, mpox

## 1 **Introduction**

2 Mpox (formerly ‘monkeypox’) is a viral zoonotic disease first identified in humans in 1970  
3 and is endemic in Central and West African countries (1). In May 2022, health authorities  
4 identified an emerging mpox outbreak in non-endemic countries, in which >95% cases were  
5 recorded among gay and bisexual and other men who have sex with men (GBMSM) (1, 2). In  
6 July 2022, the World Health Organization declared mpox a public health emergency of  
7 international concern (2). Australia made mpox a nationally notifiable disease in June 2022  
8 and declared the mpox outbreak a Communicable Disease Incident of National Significance  
9 (CDINS) in July 2022 (3). In late November 2022, the CDINS declaration was withdrawn  
10 (3).

11  
12 Mpox spreads primarily through direct contact with infected skin and bodily fluids, and by  
13 large respiratory droplets (4). Despite initial concerns of fomite transmission via  
14 contaminated surfaces, to date no such transmission has been documented during the current  
15 outbreak (4, 5). Mpox infection is self-limited and requires self-isolation until lesions have  
16 healed (6, 7). Clinical care, including hospitalisation may be required to manage secondary  
17 bacterial infections, ocular and gastrointestinal involvement and severe pain (6, 7). Mpox is  
18 rarely fatal (6, 7). More than 85,000 mpox cases have been recorded in 103 non-endemic  
19 countries, with 81 fatalities (8). Globally, the number of incident infections peaked in August  
20 2022 at around 1,000 cases daily, and have declined since then (9). Australia recorded its first  
21 mpox cases in May 2022, and 144 cases by March 2023, two-thirds of which were acquired  
22 overseas (8).

23  
24 Vaccinia vaccines, developed to protect against smallpox, offer protection against mpox (10,  
25 11). In August 2022, the Australian Government acquired a limited supply of 3<sup>rd</sup>-generation,

26 non-replicating Modified Vaccinia Ankara (MVA) vaccine, initially targeted to people at  
27 highest risk of exposure to monkeypox virus or severe mpox illness (12, 13). As was  
28 observed during COVID-19, particularly before widespread vaccine availability (14, 15),  
29 GBMSM will likely follow public health advice, promoted via community organisations, and  
30 adapt their behaviour to reduce their risk of acquiring monkeypox virus until they are  
31 vaccinated; for example by reducing the number of untraceable sexual partners and  
32 attendance at sex-on-premises venues and sex parties. Based on experience with COVID-19,  
33 we anticipate most GBMSM will be willing to be vaccinated against mpox (16, 17).

34

35 To identify education and health promotion needs for people at risk of mpox, and help guide  
36 the Australian vaccination program, we examined what GBMSM and non-binary people  
37 knew about monkeypox virus and what behavioural changes they would be prepared to  
38 undertake in response to the outbreak. We anticipated that greater concern about mpox would  
39 be associated with a greater willingness to modify behaviour and to seek vaccination.

40

## 41 **Method**

### 42 *Study design and participants*

43 A national Australian, cross-sectional survey was conducted between 24 August and  
44 12 September 2022 using Qualtrics software (Provo, UT). The survey was promoted through  
45 community partner organisations and paid advertisements on Facebook and Grindr,  
46 supplemented by email invitations to consenting participants of previous studies. Potential  
47 participants were directed to the study website, containing participant information and the  
48 survey link. Participants provided consent before starting the survey. Eligible participants  
49 identified as gay, bisexual or queer (GBQ); identified as male (cisgender or transgender) or  
50 non-binary; were aged 16 years or older; and lived in Australia. The study was approved by

51 the ethics committee of UNSW Sydney (HC220484) and the community organisation ACON  
52 (2022/14).

### 53 ***Measures***

54 We collected data on demographics, physical health, recent sexual practices, HIV status, HIV  
55 treatment or pre-exposure prophylaxis (PrEP), sexually transmissible infection (STI) testing  
56 and history, vaccination history against smallpox or mpox, knowledge and concern about  
57 mpox, acceptability of behavioural changes in response to mpox, and willingness to be  
58 vaccinated. Adaptive routing was used to exclude irrelevant items, and response options were  
59 randomised in lists to reduce order bias. Participants who had been diagnosed with mpox  
60 were shown questions about their experience of mpox (not discussed in this article). The  
61 main outcome measures are detailed in Appendix 1 (see supplementary materials).

### 62 ***Statistical analyses***

63 Descriptive statistics were computed for all variables. Pearson's chi-squared tests identified  
64 significant associations between independent and dependent variables, and logistic regression  
65 was used to identify independent associations for key dependent variables (i.e., behavioural  
66 change measures and vaccine willingness). Multivariable analyses used block entry of  
67 variables that were significant at the bivariable level. Statistical assumptions were assessed,  
68 including model diagnostics for logistic regression, none of which were violated. Variables in  
69 the regression models had no missing observations. We report unadjusted and adjusted odds  
70 ratios (OR and aOR) with 95% confidence intervals (CI). Statistical significance was set at  
71  $p < .05$  (two-tailed). Analyses were conducted using Stata version 16.1 (StataCorp, College  
72 Station, TX).

73

## 74 **Results**

75 The survey was completed by 2287 of 3232 eligible people who commenced it (70.76%  
76 completion rate). The median age of the 2287 participants was 40 years (IQR=31–51), 1894  
77 (82.82%) identified as gay, 2189 (95.71%) were male, 1701 (74.38%) were Australian born,  
78 1550 (67.77%) were university educated, 1647 (72.02%) reported full-time employment, and  
79 1877 (82.07%) lived in the capital city of their state/territory. Most participants lived in New  
80 South Wales (860; 37.60%) or Victoria (760; 33.20%). In total, 1944 (85.00%) were HIV-  
81 negative, 179 (7.83%) were HIV-positive, and 164 (7.17%) were untested or did not know  
82 their status. Within the prior 12 months, more than two thirds of the sample had been tested  
83 for HIV (1634; 71.45%) or other STIs (1616; 70.66%). In total, 1241 (54.27%) participants  
84 had ever used PrEP and 914 (39.97%) were taking PrEP at the time of the survey. Further  
85 details of participant characteristics are shown at Appendix 2, Table 1 (see supplementary  
86 materials).

87 ***Previous vaccination against smallpox or mpox.*** Nearly one quarter of participants had ever  
88 received a smallpox or mpox vaccine (541/2287; 23.66%). Most had received MVA vaccine  
89 (325/541; 60.1% of vaccinated participants or 14.21% of the total sample), a small proportion  
90 had received replication-competent 2<sup>nd</sup>-generation vaccinia vaccine (ACAM2000) (28/541;  
91 5.2%), and more than one third did not know which vaccine they had received (188/541;  
92 34.8%). Most were vaccinated after May 2022 (347/541; 64.1%), and had received the  
93 vaccine before potential exposure to mpox (283/347; 81.6%). Fifteen participants were  
94 vaccinated after potential exposure (15/347; 4.3%), and the remainder reported they received  
95 the vaccine for ‘another reason’; that is, unrelated to potential exposure to mpox (49/357;  
96 14.1%). Of participants vaccinated with MVA, most had received only one dose (320/325;

97 98.5%) and most received it in Australia (295/325; 90.8%). Further details of previous  
98 vaccination are shown at Appendix 2, Table 2.

99 **Potential mpox risk factors.** Of the 2287 participants, 706 (30.87%) had travelled overseas in  
100 the previous six months, and 1075 (47.00%) planned to travel in the next six months. In the  
101 six months preceding the survey, 599 (26.19%) participants had more than 10 male sexual  
102 partners, 1277 (55.84%) reported casual sex with male partners without condoms, 1248  
103 (54.58%) reported anonymous sex, 804 (35.16%) reported group sex, and 731 (31.96%) had  
104 visited a sex-on-premises venue. Compared with unvaccinated participants, participants  
105 vaccinated since May 2022 were more likely to report recent and future overseas travel, and  
106 other potential mpox risk factors (see Appendix 2, Table 3 for comparisons).

107 **Mpox knowledge and concern.** Of the 2268 participants who had not been diagnosed with  
108 mpox, 32 (1.41%) had never heard of mpox before the survey, 1065 (46.96%) knew a ‘small  
109 amount’, 695 (30.65%) a ‘fair amount’, 356 (15.70%) ‘quite a bit’ and 120 (5.29%) ‘a lot’.  
110 The most common ways to learn about mpox were the media (1904/2255; 84.43%),  
111 conversations with friends or family (729/2255; 32.33%), and information provided by  
112 community organisations (660/2255; 29.27%). Among the 2268 undiagnosed participants,  
113 323 (14.24%) knew someone who had been diagnosed with mpox, 1461 (64.42%) were  
114 concerned or very concerned about acquiring mpox, and 465 (20.50%) believed it likely or  
115 very likely they would acquire mpox. Vaccinated participants were more likely to report  
116 mpox knowledge and concern compared to unvaccinated participants, but there was no  
117 difference in perceived likelihood of acquiring mpox (see Appendix 2, Table 4 for all  
118 comparisons).

119 **Recognition of mpox symptoms and transmission routes.** The 2268 undiagnosed  
120 participants were asked to identify potential mpox symptoms and transmission routes. The  
121 most commonly identified symptoms were skin lesions (2087; 92.02%), skin rash (1977;



122 87.17%), and fever (1647; 72.62%). Fig. 1 shows other symptoms and uncertainty about  
123 potential symptoms (ranging from 5–43% for ‘don’t know’ responses).

124 Most participants identified prolonged skin-to-skin contact (2124; 93.65%), brief skin-to-skin  
125 contact (1860; 82.01%) and contact with bodily fluids (1692; 74.60%) as potential ways to  
126 acquire mpox. Fig. 2 shows knowledge of transmission routes and uncertainty about them  
127 (ranging from 5–36%). Participants with more than 10 male sexual partners in the previous  
128 six months were more likely to recognise potential mpox symptoms (and some transmission  
129 routes) compared to those with fewer partners (see Appendix 2, Table 5 for all comparisons).

130 ***Acceptability of behavioural changes in response to mpox.*** Fig. 3 shows the acceptability of  
131 different behavioural changes among the 2268 undiagnosed participants. The most acceptable  
132 strategies were reducing or avoiding attendance at sex parties (1494; 65.87%) and sex-on-  
133 premises venues (1503; 66.40%), and having fewer sexual partners (1466; 64.64%).

134 Multivariable analyses showed that concern about mpox and vaccination since May 2022  
135 were independently associated with greater acceptability of these three strategies (see  
136 Appendix 2, Table 6 for multivariable results). The least acceptable strategies were not  
137 hugging people (445; 19.62%), avoiding densely populated venues (760; 33.51%), and not  
138 kissing people (771; 33.99%). Most participants were willing to avoid contact with people if  
139 diagnosed with mpox (2110/2268; 93.03%), but fewer participants were confident they could  
140 avoid physical contact with people (1660/2268; 73.19%), work from home (1588/2268;  
141 70.02%), or not share communal living spaces such as a bathroom, kitchen or bedroom  
142 (1222/1268; 53.88%). More than half of participants were comfortable with contact tracers  
143 disclosing a potential mpox diagnosis to casual sex partners (1377/2268; 60.71%; see  
144 Appendix 2, Table 7 for further details).

145 ***Willingness to be vaccinated against mpox.*** Among the 1733 participants who were  
146 unvaccinated and had not been diagnosed with mpox, 1457 were willing to be vaccinated

147 (84.07%). Most were willing to receive the vaccine immediately as a precautionary measure  
148 (1337/1733; 77.15%); a smaller proportion indicated they would be vaccinated later if more  
149 mpox cases were reported in Australia (268/1733; 15.46%). Among the 1486 participants  
150 who had at least one male casual sex partner in the previous six months, vaccine acceptability  
151 was similar to the broader group (1275/1486, 85.80% vs. 1457/1733, 84.07%). Multivariable  
152 analysis showed bisexual participants and those who were unconcerned about mpox were less  
153 willing to be vaccinated and participants with greater numbers of recent sexual partners were  
154 more willing (see Appendix 2, Table 8 for multivariable results).

155

## 156 **Discussion**

157 This was the first national study of knowledge and attitudes to mpox among GBMSM in  
158 Australia. Most participants accurately identified common clinical symptoms (skin lesions  
159 and/or rash) and transmission routes (skin-to-skin contact). Early recognition of symptoms is  
160 an important component of public health responses to an infectious disease outbreak.

161

162 Nearly one quarter of participants reported a history of smallpox or mpox vaccination. As  
163 Australia never had universal smallpox vaccination (18, 19) and estimates suggest only 10%  
164 of contemporary Australians have been vaccinated against smallpox (20), it is likely that  
165 some participants mistakenly believed they had been vaccinated (21). It is unknown whether  
166 mistaken beliefs about historical vaccination may deter people from seeking vaccination  
167 against mpox, but it may be important for public education campaigns to highlight the limited  
168 coverage and protection offered by historical smallpox vaccination (7).

169

170 As we anticipated, almost two thirds of participants were willing to modify their sexual  
171 practices to reduce their risk of acquiring mpox (e.g., avoiding sex parties, sex-on-premises

172 venues or having fewer sex partners). However, changes to social practices, such as avoiding  
173 hugging or kissing, or avoiding popular venues, were rated as less acceptable. It is possible  
174 that changes to social behaviour were perceived as less acceptable after COVID-19  
175 restrictions in Australia ('pandemic fatigue') (22) and because GBMSM correctly surmised  
176 that prolonged skin-to-skin contact represents a greater transmission risk. Previous research  
177 has found that GBMSM are unwilling to avoid kissing to reduce the risk of gonorrhoea (23).  
178 However, COVID-19 research showed that GBMSM modified their sexual practices to  
179 reduce transmission risk, particularly in the absence of vaccine protection (15, 17), gradually  
180 increasing levels of sexual activity after they were vaccinated (24). It is difficult for people to  
181 sustain behaviour that has a personal or social cost over time (25), so public health messages  
182 should consider what behaviour change may be achievable and acceptable for GBMSM  
183 during mpox outbreaks, in order for messaging to be effective. Ongoing surveillance of  
184 sexual behaviour, vaccine uptake, and behaviour change in response to mpox would be  
185 useful.

186

187 Lastly, there was very high willingness to receive mpox vaccination as it becomes available.  
188 Few factors distinguished between participants who were willing to be vaccinated or not,  
189 although bisexual participants and people who were less concerned about mpox were less  
190 willing, and people with more sexual partners were more willing. In general, this aligns with  
191 community-oriented messaging about mpox vaccination, which encouraged more sexually  
192 active people to come forward first, when vaccine supplies were limited. Our results suggest  
193 that targeted messaging for bisexual men may be warranted, explaining why vaccination is  
194 beneficial, and how vaccination may be accessed safely and discreetly. Such messaging may  
195 be particularly important to increase mpox vaccination rates to reduce the risk of future  
196 outbreaks, given mpox may circulate globally at low levels for the foreseeable future.

197 **Limitations**

198 We acknowledge the limitations of the analysis, which included the study's non-random  
199 sample. As there are limited national data on GBMSM and non-binary people, the  
200 representativeness of our sample is unknown. However, the cross-sectional sample comprised  
201 a large proportion of people who were at potential risk of acquiring mpox (i.e., who reported  
202 potential risk behaviours, recent travel and future travel plans). Further, 19 (14.7%) of the  
203 129 people (as of 12 September 2022) who had been diagnosed with mpox in Australia  
204 responded to the survey (9). We also oversampled participants from New South Wales and  
205 Victoria, where most mpox cases were reported (3). Our findings may therefore reflect the  
206 experiences of people with greater interest in mpox or those at risk of acquiring mpox in  
207 Australia.

208


209 **Conclusion**

210 Despite the rapid global emergence of mpox, Australia is well placed to avoid a large-scale  
211 local mpox outbreak. This can be achieved through large-scale uptake of mpox vaccination  
212 by at-risk people, and targeted education and awareness raising among GBMSM to explain  
213 the importance of temporary modifications of sexual practices during outbreaks while  
214 vaccination levels increase. Our survey indicates high levels of willingness to receive mpox  
215 vaccination, but some populations, namely bisexual men and GBMSM with lower numbers  
216 of sexual partners, may benefit from encouragement and support to get vaccinated. Our  
217 survey indicates that GBMSM are willing to modify some sexual practices to reduce their  
218 risk of mpox, but we caution that such behaviour modification may not be sustainable in the  
219 longer term, and hence risk reduction messaging must be carefully timed to achieve maximal  
220 impact during periods where there is a risk of transmission. Together, our findings suggest  
221 many GBMSM seek to protect their own and others' sexual health, but some groups may

222 need additional support to access health information, vaccination, and health services. While  
223 case numbers are currently low, Australia should seize the opportunity to increase  
224 vaccination coverage to reduce the chance of future outbreaks.


## FIGURES

**Figure 1 – Mpox symptom identification by 2268 participants who had not been diagnosed with mpox**



All potential mpox symptoms were presented in random order. Three 'decoy' symptoms were included in the survey but are not reported here, e.g., 'loss of taste or smell'.


**Figure 2 – Mpox transmission route identification by 2268 participants who had not been diagnosed with mpox**



All potential mpox transmission routes were presented in random order.

**Figure 3 – Endorsement of potential mpox risk-reduction strategies by 2268**

**participants who had not been diagnosed with mpox**



\*This item was only shown to the 1733 participants who had not received a smallpox/mpox vaccination or been diagnosed with mpox. All items were presented in random order.



## **DECLARATIONS**

### ***Author contributions***

All authors contributed to the study design, analysis and interpretation of findings. James MacGibbon, Timothy R Broady and Martin Holt oversaw data collection. James MacGibbon drafted the manuscript and conducted the quantitative analyses, supported by Vincent Cornelisse and Martin Holt. All authors reviewed and commented on drafts of the manuscript and agreed with the final version.

### ***Acknowledgements***

In-kind creative services for the study recruitment materials and website were provided by Oskar Westerdal and Vincent Rommelaere. We are grateful to Professor Andrew Grulich and Timmy Lockwood who provided advice on the survey instrument.

### ***Declaration of funding***

The Centre for Social Research in Health and Kirby Institute receive funding from the Australian Government Department of Health and from state/territory health departments. The funding sources did not have any involvement in the collection, analysis and interpretation of data, or in the writing of this manuscript and decision to submit for publication. No pharmaceutical funding was received for this study.

### ***Conflicts of Interest***

Anthony K J Smith is a Joint Editor of *Sexual Health*, but was blinded from the peer-review process for this paper.

### ***Availability of data and material***

A deidentified dataset may be available from the authors upon reasonable request, subject to ethical oversight being obtained by bona fide researchers.

### ***Code availability***

Syntax for the database coding and analysis may be available upon request.

### ***Compliance with ethical standards***

The questionnaire and methodology for this study were approved by the Human Research Ethics Committee of UNSW Sydney (HC220484) and endorsed by the community organisation ACON (2022/14). Informed consent was obtained from all individual participants included in the study prior to their participation in the questionnaire.

## REFERENCES

1. Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ, et al. Heavy-tailed sexual contact networks and monkeypox epidemiology in the global outbreak, 2022. *Science*. 2022;378(6615):90-4.
2. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 countries — April–June 2022. *N Engl J Med*. 2022;387(8):679-91.
3. Australian Government: Department of Health and Aged Care. Mpox (monkeypox) health alert 2023 [Available from: <https://www.health.gov.au/diseases/monkeypox-mpox>].
4. Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. *J Autoimmun*. 2022;131:102855.
5. US Centers for Disease Control and Prevention. Science brief: Detection and transmission of monkeypox virus 2022 [Available from: <https://www.cdc.gov/poxvirus/monkeypox/about/science-behind-transmission.html>].
6. Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: An observational analysis. *The Lancet Infectious Diseases*. 2022;22(9):1321-8.
7. MacIntyre CR, Grulich AE. Is Australia ready for monkeypox? *Med J Aust*. 2022;217(4):193-4.
8. US Centers for Disease Control and Prevention. Monkeypox outbreak global map 2023 [06/07/22]. Available from: <https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html>.

9. Mathieu E, Spooner F, Dattani S, Ritchie H, Roser M. Monkeypox Published online at OurWorldInData.org: OurWorldInData.org; 2022 [Available from: <https://ourworldindata.org/monkeypox>].
10. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. *Nat Med*. 2005;11(9):1005-11.
11. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. *Drugs*. 2022;82(9):957-63.
12. Australian Technical Advisory Group on Immunisation [ATAGI]. Updated ATAGI clinical guidance on vaccination against MPX (monkeypox): August 2022 2022 [Available from: <https://www.health.gov.au/sites/default/files/documents/2022/08/atagi-clinical-guidance-on-vaccination-against-monkeypox.pdf>].
13. Chow EPF, Chen MY, Bradshaw CS, Towns JM, Fairley CK. Accessing first doses of mpox vaccine made available in Victoria, Australia. *The Lancet Regional Health - Western Pacific*. 2023;31:100712.
14. Murphy D, Ellard J, Maher L, Saxton P, Holt M, Haire B, et al. How to have sex in a pandemic: the development of strategies to prevent COVID-19 transmission in sexual encounters among gay and bisexual men in Australia. *Cult Health Sex*. 2022:1-16.
15. Hammoud MA, Maher L, Holt M, Degenhardt L, Jin F, Murphy D, et al. Physical distancing due to COVID-19 disrupts sexual behaviors among gay and bisexual men in Australia: Implications for trends in HIV and other sexually transmissible infections. *J Acquir Immune Defic Syndr*. 2020;85(3):309-15.
16. Holt M, MacGibbon J, Bavinton B, Broady T, Clackett S, Ellard J, et al. COVID-19 vaccination uptake and hesitancy in a national sample of Australian gay and bisexual men. *AIDS Behav*. 2022;26(8):2531-8.

17. Prestage G, Storer D, Jin F, Haire B, Maher L, Philpot S, et al. COVID-19 vaccine uptake and its impacts in a cohort of gay and bisexual men in Australia. *AIDS Behav.* 2022;26(8):2692-702.
18. Kennedy RB, Lane JM, Henderson DA, Poland GA. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines (Sixth Edition)*. London: W.B. Saunders; 2013. p. 718-45.
19. Costantino V, Trent MJ, Sullivan JS, Kunasekaran MP, Gray R, MacIntyre R. Serological immunity to smallpox in New South Wales, Australia. *Viruses.* 2020;12(5).
20. MacIntyre CR, Costantino V, Chen X, Segelov E, Chughtai AA, Kelleher A, et al. Influence of population immunosuppression and past vaccination on smallpox reemergence. *Emerg Infect Dis.* 2018;24(4):646-53.
21. Durrheim DN, Muller R, Saunders V, Speare R, Lowe JB. Australian public and smallpox. *Emerg Infect Dis.* 2005;11(11):1748-50.
22. World Health Organization. Regional Office for Europe. Pandemic fatigue: reinvigorating the public to prevent COVID-19: policy framework for supporting pandemic prevention and management: revised version November 2020 2020 [Available from: <https://apps.who.int/iris/handle/10665/337574>].
23. Chow EPF, Walker S, Phillips T, Fairley CK. Willingness to change behaviours to reduce the risk of pharyngeal gonorrhoea transmission and acquisition in men who have sex with men: a cross-sectional survey. *Sex Transm Infect.* 2017;93(7):499-502.
24. Holt M, Chan C, Broady TR, Mao L, MacGibbon J, Rule J, et al. Adjusting behavioural surveillance and assessing disparities in the impact of COVID-19 on gay and bisexual men's HIV-related behaviour in Australia. *AIDS Behav.* 2022.
25. Kelly MP, Barker M. Why is changing health-related behaviour so difficult? *Public Health.* 2016;136:109-16.

